Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00DQX
|
||||
| Former ID |
DCL000578
|
||||
| Drug Name |
Motesanib
|
||||
| Synonyms |
AMG 706; AMG706; AMG-706; N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-3-pyridinecarboxamide; N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4-ylmethyl)amino]pyridine-3-carboxamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
Amgen
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H23N5O
|
||||
| InChI |
InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28)
|
||||
| InChIKey |
RAHBGWKEPAQNFF-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 453562-69-1
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
16771727, 23766907, 47208329, 50100087, 56269724, 56394911, 57376990, 79661629, 85195381, 103694305, 109693533, 123044253, 123051115, 125711982, 126584079, 126634886, 126665970, 126728315, 134339136, 135216214, 135685150, 135685151, 135685170, 135686092, 135686093, 135686110, 135686111, 136368105, 137010936, 137276049, 142660693, 143498107, 144115596, 152234936, 152258139, 152344215, 160646978, 162201686, 163108960, 164043534, 164230685, 174561000, 177748728, 178102288, 180371640, 184826919, 198946291, 223385949, 223670551, 226547309
|
||||
| ChEBI ID |
ChEBI:51098
|
||||
| Target and Pathway | |||||
| Target(s) | Platelet-derived growth factor receptor | Target Info | Inhibitor | [537551], [550250], [551087] | |
| Vascular endothelial growth factor receptor 2 | Target Info | Inhibitor | [537551], [550250], [551087] | ||
| Mast/stem cell growth factor receptor | Target Info | Inhibitor | [537551], [550250], [551087] | ||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| VEGF signaling pathway | |||||
| Focal adhesion | |||||
| Proteoglycans in cancerhsa04014:Ras signaling pathway | |||||
| Hematopoietic cell lineage | |||||
| Melanogenesis | |||||
| Pathways in cancer | |||||
| Acute myeloid leukemia | |||||
| Central carbon metabolism in cancer | |||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY networkcmyb_pathway:C-MYB transcription factor network | |||||
| Signaling events mediated by Stem cell factor receptor (c-Kit) | |||||
| Reactome | Neurophilin interactions with VEGF and VEGFR | ||||
| VEGF binds to VEGFR leading to receptor dimerization | |||||
| Integrin cell surface interactions | |||||
| EPHA-mediated growth cone collapse | |||||
| VEGFA-VEGFR2 Pathway | |||||
| VEGFR2 mediated cell proliferationR-HSA-1257604:PIP3 activates AKT signaling | |||||
| Regulation of KIT signaling | |||||
| Constitutive Signaling by Aberrant PI3K in Cancer | |||||
| RAF/MAP kinase cascade | |||||
| WikiPathways | Focal Adhesion | ||||
| Nifedipine Activity | |||||
| Cardiac Progenitor Differentiation | |||||
| Signaling by VEGF | |||||
| AngiogenesisWP304:Kit receptor signaling pathway | |||||
| Differentiation Pathway | |||||
| Signaling by SCF-KIT | |||||
| PIP3 activates AKT signaling | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| miR-targeted genes in lymphocytes - TarBase | |||||
| miR-targeted genes in epithelium - TarBase | |||||
| References | |||||
| Ref 541005 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5660). | ||||
| Ref 546905 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011016) | ||||
| Ref 537551 | Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009 Aug 10;27(23):3794-801. Epub 2009 Jun 29. | ||||
| Ref 550250 | Clinical pipeline report, company report or official report of Amgen (2009). | ||||
| Ref 551087 | Axitinib for renal cell carcinoma. Expert Opin Investig Drugs. 2008 May;17(5):741-8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.